TRIUMF

NSERC Awards Funding to TRIUMF and General Fusion to Develop State-of-the-Art Diagnostic System for LM26 Fusion Machine

Retrieved on: 
Wednesday, March 27, 2024
Natural science, Plasma, University, Health, Science, Research, General Fusion, Neutron, Engineering, TRIUMF, Simon Fraser University, Lithium

The neutron spectrometer system is a flagship project under the collaborative agreement signed by TRIUMF and General Fusion in 2023 .

Key Points: 
  • The neutron spectrometer system is a flagship project under the collaborative agreement signed by TRIUMF and General Fusion in 2023 .
  • Known for pushing the boundaries of science and innovation, TRIUMF will support General Fusion in developing a diagnostic system capable of precisely measuring neutron energies at a very high rate.
  • Neutrons carry unique information about fusion reactions, and the system being built at TRIUMF and General Fusion will tag neutron interactions every nanosecond.
  • “This exciting project highlights the deep technology collaboration happening across the country to advance Canadian fusion energy technology,” said Greg Twinney, CEO, General Fusion.

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

Retrieved on: 
Monday, March 4, 2024
Acquisition, Pharmacy, TMS, TRIUMF, Actinium-225, Chemistry, Isotope, Sale, TLX, Physics, ASX, Clinical trial, Science, Ultra, Research, Partnership, Medical imaging

MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.

Key Points: 
  • MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.
  • Telix is currently validating multiple production locations of large-scale 89Zr production in the United States (U.S.) using the QIS system and select manufacturing and pharmacy partners.
  • ARTMS and Telix have been collaborating since 20202 to evaluate the potential of higher curie-scale (Ci) production of Illuccix®.
  • As part of the acquisition, Telix will also acquire the benefit of ARTMS’s production facility and clean rooms, located in Burnaby, BC (Canada).

General Fusion and TRIUMF sign MOU to develop key technologies for new LM26 fusion machine

Retrieved on: 
Wednesday, October 25, 2023
Knowledge, Science, General Fusion, Plasma, Magnetized target fusion, TRIUMF, Power, Electricity, Research, Nuclear physics, MOU, MTF, Physics, Lithium, 3D printing

This groundbreaking machine is designed to reach fusion conditions in 2025 and set a path for scientific breakeven equivalent in 2026.

Key Points: 
  • This groundbreaking machine is designed to reach fusion conditions in 2025 and set a path for scientific breakeven equivalent in 2026.
  • TRIUMF and General Fusion will collaborate on projects in key areas including neutron diagnostics and a state-of-the-art ion temperature diagnostic for LM26.
  • “British Columbia is a hub for technology innovation and General Fusion is pleased to advance our transformative LM26 machine with an organization that is both local and has international renown,” said Greg Twinney, CEO, General Fusion.
  • General Fusion will leverage TRIUMF’s existing capabilities in high energy particle physics, materials science and testing to support the development of General Fusion’s Magnetized Target Fusion technology.

TRIUMF Innovations and the Centre for Probe Development and Commercialization to Receive up to $35 Million in Funding for their Canadian Medical Isotope Ecosystem

Retrieved on: 
Tuesday, June 27, 2023
Canadian Nuclear Laboratories Research Facilities, Commercialization, The Honourable, McMaster Nuclear Reactor, Cancer, Strategic Innovation Fund, Research, Radiopharmaceutical, Government, Investment, Economic development, Ecosystem, Health, Innovation, Science and Economic Development Canada, SME, TRIUMF, Pharmaceutical industry, Medical imaging, Science

The Canadian Medical Isotope Ecosystem will support the development, production, advancement and distribution of isotopes, and position Canada as an international medical isotope powerhouse

Key Points: 
  • Vancouver, British Columbia, and Hamilton, Ontario--(Newsfile Corp. - June 27, 2023) - TRIUMF Innovations and the Centre for Probe Development and Commercialization (CPDC) today announced they will receive up to $35 million in funding for the creation of the new Canadian Medical Isotope Ecosystem (CMIE).
  • Over the term of the funding, CMIE is expected to launch three high-demand medical isotopes and related drug products into the marketplace.
  • "Our government is proud to partner with CPDC and TRIUMF Innovations as part of our Biomanufacturing and Life Sciences Strategy to create the Canadian Medical Isotope Ecosystem.
  • With TRIUMF Innovations' focus on commercialization, we are pleased with this new level of support for medical isotope commercialization from Minister Champagne and the Canadian government."

Government of Canada teams up with Indigenous partners, Bruce Power and the medical isotope community to fight cancer

Retrieved on: 
Tuesday, June 27, 2023
SON, Canadian Nuclear Laboratories Research Facilities, Saugeen Ojibway Nation Territory, Partnership, Commercialization, Sickness, McMaster Nuclear Reactor, Marketing, Framatome, Chippewas of Nawash Unceded First Nation, Cancer, Saugeen First Nation, Research, Ytterbium, Parliament, Nuclear medicine, Bruce Power, Hon, Patient, Physician, Investment, Public security, Government of Canada, Ecosystem, Federation, Health, Isotope, Oakville North—Burlington, IPS, Safety, TRIUMF, Rare-earth element, Uranium mining, Medical imaging, Renewable energy, Pharmaceutical industry, Science, Isogenic human disease models, Ojibwe

The partnership includes Indigenous communities, Ontario’s nuclear industry, and leading research facilities, academics, and firms working to commercialize novel therapies.

Key Points: 
  • The partnership includes Indigenous communities, Ontario’s nuclear industry, and leading research facilities, academics, and firms working to commercialize novel therapies.
  • This funding will ultimately enable a pan-Canadian consortium – the Canadian Medical Isotope Ecosystem (CMIE) – to advance and accelerate the development of the next generation of novel medical isotopes and technologies.
  • “Canada is a world leader in medical isotope research and production, and Bruce Power is proud to be among the innovative companies that places Canada at the forefront of nuclear medicine,” said Mike Rencheck, Bruce Power’s President and CEO.
  • “Our government is proud to partner in the creation of the Canadian Medical Isotope Ecosystem, which includes support for the SON First Nations communities’ partnership with Bruce Power to innovate in the fight against cancer,” said Minister Champagne.

TRIUMF expands, fortifies member university network

Retrieved on: 
Monday, March 6, 2023
University, Research, TRIUMF, Management

Vancouver, March 06, 2023 (GLOBE NEWSWIRE) -- TRIUMF , Canada’s particle accelerator centre, announced today that it has expanded its national member consortium, adding seven new universities to its network.

Key Points: 
  • Vancouver, March 06, 2023 (GLOBE NEWSWIRE) -- TRIUMF , Canada’s particle accelerator centre, announced today that it has expanded its national member consortium, adding seven new universities to its network.
  • Together, the addition of seven new members signals a strong message of support for TRIUMF from Canada’s universities.
  • “TRIUMF is very pleased to see such a strong response from our research communities and member universities,” said Lisa Kalynchuk, Vice-Chair, TRIUMF Board of Governors.
  • “This shows a clear recognition of the value of TRIUMF as a national and strategic science asset today, as well as a resounding vote of confidence for the vision for TRIUMF for the next 20 years and beyond.”
    TRIUMF’s member universities are empowered to participate in and lead elements of the TRIUMF science program, including the laboratory’s vision-setting and its multifaceted and intersectional portfolio of collaborations and network opportunities.

Alpha-9 Theranostics Strengthens its Scientific Expertise with Key Appointments to Leadership Team and Scientific Advisory Board

Retrieved on: 
Tuesday, March 7, 2023
USDOE, Radiochemistry, CSO, IAEA, Therapy, Radiopharmaceutical, Research, Growth, Royal, NAS, Royal Society, Drug discovery, Patient, Radionuclide, PET, United States Air Force Scientific Advisory Board, University of Texas Health Science Center Department of Radiology, Knowledge, Roche, R, UBC, Memorial Sloan Kettering Cancer Center, TRIUMF, Senior, SAB, Pharmaceutical industry, Medical imaging

BOSTON and VANCOUVER, BC, March 7, 2023 /PRNewswire/ -- Alpha-9 Theranostics, a clinical stage biotechnology company developing differentiated and highly targeted radiopharmaceuticals, today announced the appointment of Jutta Wanner, Ph.D. as Senior Vice President of Drug Discovery. The company also announced the appointments of Jason Lewis, Ph.D. and Tom Ruth, Ph.D. to the newly formed Scientific Advisory Board.

Key Points: 
  • The company also announced the appointments of Jason Lewis, Ph.D. and Tom Ruth, Ph.D. to the newly formed Scientific Advisory Board.
  • "We are thrilled to welcome these experts to our team," said David Hirsch, M.D., Ph.D., CEO of Alpha-9.
  • I am excited to build out the R&D team and look forward to moving into our new lab space."
  • Dr. Jason Lewis brings deep expertise in the development and translation of radiopharmaceuticals from decades of research developing small- and biomolecule-based therapeutics and diagnostics.

CNL and TRIUMF to Collaborate on Nuclear Science & Technology

Retrieved on: 
Tuesday, January 24, 2023
Health, Public health, MOU, Government of Canada, Triangle Universities Nuclear Laboratory, TRIUMF, CNL, Intellectual property, Partnership, Environment, Nuclear physics, Science and technology, Organization, Government, Radiation, Research, Uranium, Science

CHALK RIVER, Ontario and VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology laboratory, and TRIUMF, Canada’s particle accelerator centre, are pleased to announce that they have signed a memorandum of understanding (MOU) to explore and pursue collaboration opportunities in nuclear and materials science and technology. Designed to foster closer ties between two of Canada’s leading nuclear research organizations and leverage their complementary capabilities, the new agreement identifies areas of cooperation that includes the delivery of joint research projects and the sharing of scientific information and equipment.

Key Points: 
  • CHALK RIVER, Ontario and VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology laboratory, and TRIUMF, Canada’s particle accelerator centre, are pleased to announce that they have signed a memorandum of understanding (MOU) to explore and pursue collaboration opportunities in nuclear and materials science and technology.
  • This agreement is an opportunity to accelerate key areas of research and innovation, better utilize CNL and TRIUMF’s respective resources to accomplish shared goals, and continue leveraging national science infrastructure for the benefit of Canadians.
  • “CNL and TRIUMF have worked together constructively in the past to pursue joint research, and we see this agreement as an opportunity to really grow this relationship into the future,” commented Dr. Jeff Griffin, CNL’s Vice-President of Science and Technology.
  • To learn more about TRIUMF and their work as Canada’s particle accelerator centre, please visit www.triumf.ca .

Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. as Chief Medical Officer

Retrieved on: 
Monday, November 7, 2022
Employment, Board, DNA, FGFR3, Merck, TRIUMF, Neoplasm, Acquisition, Neurotensin receptor, Isotope, View, AstraZeneca, Cancer, Radiopharmaceutical, IND, Financial compensation, Multimedia, Tesaro, TAT, NTSR1, Leadership, Regeneron Pharmaceuticals, Pembrolizumab, Patient, Corporate communication, Clinical trial, Tat, FDA, Pharmaceutical industry, Checkmate, Sanofi, Fusion

HAMILTON, ONandBOSTON, Nov. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical officer.

Key Points: 
  • HAMILTON, ONandBOSTON, Nov. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical officer.
  • Dr. Bobilev joins Fusion from Checkmate Pharma, where he was vice president, head of clinical development until the company's acquisition by Regeneron earlier in 2022.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA (pembrolizumab) in patients with solid tumors expressing IGF-1R.

Fusion Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, September 7, 2022
AstraZeneca, Tat, DNA, IND, View, Neurotensin receptor, Morgan, NTSR1, TRIUMF, Isotope, Multimedia, Pembrolizumab, Corporate communication, Conference, Company, FDA, Neoplasm, Merck, Webcast, FGFR3, Patient, Pharmaceutical industry, Fusion

HAMILTON, ON and BOSTON, Sept. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference onWednesday, September 14, 2022at12:55 p.m.

Key Points: 
  • HAMILTON, ON and BOSTON, Sept. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference onWednesday, September 14, 2022at12:55 p.m.
  • A replay of the webcast will be archived on the Company's website for 60 days following the presentation.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors.